公开(公告)号：US6025388A

公开(公告)日：2000-02-15

申请号：US428957

申请日：1995-04-26

申请人： Sunil Nagpal ,  Tae K. Song ,  Vidyasagar Vuligonda ,  Jyoti Athanikar ,  Roshantha A. Chandraratna

发明人： Sunil Nagpal ,  Tae K. Song ,  Vidyasagar Vuligonda ,  Jyoti Athanikar ,  Roshantha A. Chandraratna

IPC分类号： C07D309/12 ,  A61K31/35 ,  A61K31/351 ,  A61K31/443 ,  A61K31/455 ,  A61P9/10 ,  A61P17/00 ,  A61P35/02 ,  A61P43/00 ,  C07D405/12 ,  A01N43/16 ,  A01N43/40

CPC分类号： A61K31/351 ,  A61K31/455

摘要： Retinoid compounds which repress expression of the gene promoted by AP1 protein but which do not significantly activate expression of the genes having RA-responsive elements in their promoter region through RAR.alpha. and RAR.GAMMA. receptor subtypes, are used, with reduced side effects, for treating diseases and conditions which are responsive to therapy with retinoids.

摘要翻译： 使用抑制由AP1蛋白促进的基因表达而不通过RARα和RAR GAMMA受体亚型显着激活其启动子区域中具有RA应答元件的基因的表达的类视黄醇化合物，具有减少的副作用，用于治疗 对类维生素A治疗有反应的疾病和病症。

公开(公告)号：US06369100B1

公开(公告)日：2002-04-09

申请号：US09482589

申请日：2000-01-13

申请人： Sunil Nagpal ,  Tae K. Song ,  Vidyasagar Vuligonda ,  Jyoti Athanikar ,  Roshantha A. Chandraratna

发明人： Sunil Nagpal ,  Tae K. Song ,  Vidyasagar Vuligonda ,  Jyoti Athanikar ,  Roshantha A. Chandraratna

IPC分类号： A61K4312

CPC分类号： A61K31/351 ,  A61K31/455

摘要： Retinoid compounds which repress expression of the gene promoted by AP1 protein but which do not significantly activate expression of the genes having RA-responsive elements in their promoter region through RAR&agr; and RAR&Ggr; receptor subtypes, are used, with reduced side effects, for treating diseases and conditions which are responsive to therapy with retinoids.

摘要翻译： 抑制由AP1蛋白促进的基因表达的视黄醛化合物，但通过RARalpha和RAR＆Ggr不显着激活其启动子区域中具有RA反应元件的基因的表达; 受体亚型，具有减少的副作用，用于治疗对类维生素A治疗有反应的疾病和病症。

公开(公告)号：US5877207A

公开(公告)日：1999-03-02

申请号：US880823

申请日：1997-06-24

申请人： Elliott S. Klein ,  Alan T. Johnson ,  Andrew M. Standeven ,  Richard L. Beard ,  Samuel J. Gillett ,  Tien T. Duong ,  Sunil Nagpal ,  Vidyasagar Vuligonda ,  Min Teng ,  Roshantha A. Chandraratna

发明人： Elliott S. Klein ,  Alan T. Johnson ,  Andrew M. Standeven ,  Richard L. Beard ,  Samuel J. Gillett ,  Tien T. Duong ,  Sunil Nagpal ,  Vidyasagar Vuligonda ,  Min Teng ,  Roshantha A. Chandraratna

IPC分类号： C07D333/24 ,  A61K31/245 ,  A61K31/353 ,  A61K31/381 ,  A61P3/10 ,  A61P17/16 ,  A61P19/08 ,  A61P39/02 ,  A61P43/00 ,  C07C57/50 ,  C07C63/33 ,  C07C63/49 ,  C07C63/66 ,  C07C63/72 ,  C07C63/74 ,  C07C65/19 ,  C07C65/28 ,  C07C65/38 ,  C07C69/618 ,  C07C69/76 ,  C07C69/90 ,  C07C69/94 ,  C07C233/81 ,  C07C233/87 ,  C07C245/10 ,  C07C327/48 ,  C07D213/55 ,  C07D277/30 ,  C07D307/54 ,  C07D311/58 ,  C07D335/06 ,  C07F7/08 ,  C07F7/18 ,  A61K31/35 ,  C07D311/04

CPC分类号： C07C57/50 ,  C07C233/81 ,  C07C233/87 ,  C07C245/10 ,  C07C327/48 ,  C07C63/33 ,  C07C63/49 ,  C07C63/66 ,  C07C63/72 ,  C07C63/74 ,  C07C65/19 ,  C07C65/28 ,  C07C65/38 ,  C07C69/618 ,  C07C69/76 ,  C07C69/90 ,  C07C69/94 ,  C07D213/55 ,  C07D277/30 ,  C07D307/54 ,  C07D311/58 ,  C07D333/24 ,  C07D335/06 ,  C07F7/0818 ,  C07C2102/10 ,  C07C2102/28

摘要： Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

公开(公告)号：US5958954A

公开(公告)日：1999-09-28

申请号：US998319

申请日：1997-12-24

申请人： Elliott S. Klein ,  Alan T. Johnson ,  Andrew M. Standeven ,  Richard L. Beard ,  Samuel J. Gillett ,  Tien T. Duong ,  Sunil Nagpal ,  Vidyasagar Vuligonda ,  Min Teng ,  Roshantha A. Chandraratna

发明人： Elliott S. Klein ,  Alan T. Johnson ,  Andrew M. Standeven ,  Richard L. Beard ,  Samuel J. Gillett ,  Tien T. Duong ,  Sunil Nagpal ,  Vidyasagar Vuligonda ,  Min Teng ,  Roshantha A. Chandraratna

IPC分类号： A61K31/165 ,  A61K31/19 ,  A61K31/192 ,  A61K31/216 ,  A61K31/341 ,  A61K31/35 ,  A61K31/352 ,  A61K31/353 ,  A61K31/382 ,  A61K31/426 ,  A61K31/427 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4418 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/47 ,  A61K31/655 ,  A61P3/06 ,  A61P17/00 ,  A61P19/00 ,  A61P25/04 ,  A61P39/02 ,  C07C63/06 ,  C07C65/38 ,  C07C69/78 ,  C07C233/65 ,  C07D213/55 ,  C07D215/14 ,  C07D233/66 ,  C07D277/20 ,  C07D277/30 ,  C07D307/54 ,  C07D311/04 ,  C07D311/58 ,  C07D333/24 ,  C07D335/06 ,  C07D401/12 ,  C07D405/06 ,  C07D409/04 ,  C07D409/14 ,  C07D417/04 ,  C07F7/04

CPC分类号： C07D335/06 ,  C07D213/55 ,  C07D277/30 ,  C07D307/54 ,  C07D311/58 ,  C07D333/24 ,  C07D409/04 ,  C07D417/04

摘要： 2,2-Dialkyl-4-aryl-substituted benzopyran and benzothiopyran derivatives of the formula ##STR1## where the symbols have the meaning described in the specification, have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists.

摘要翻译： 式中的2,2-二烷基-4-芳基取代的苯并吡喃和苯并噻喃衍生物，其中符号具有说明书中描述的含义，具有类视黄醇阴性激素和/或拮抗剂样生物活性。 本发明的RAR拮抗剂可以施用于包括人在内的哺乳动物，以预防或减少RAR激动剂在结合受体位点上的作用。 具体来说，RAR激动剂与类视黄醇药物一起施用或共同施用以预防或改善由类维生素A或维生素A或维生素A前体引起的毒性或副作用。 类视黄醇阴性激素可用于增强其他类维生素A和核受体激动剂的活性。

公开(公告)号：US06228848B1

公开(公告)日：2001-05-08

申请号：US09447082

申请日：1999-11-22

申请人： Elliott S. Klein ,  Alan T. Johnson ,  Andrew M. Standeven ,  Richard L. Beard ,  Samuel J. Gillett ,  Tien T. Duong ,  Sunil Nagpal ,  Vidyasagar Vuligonda ,  Min Teng ,  Roshantha A. Chandraratna

发明人： Elliott S. Klein ,  Alan T. Johnson ,  Andrew M. Standeven ,  Richard L. Beard ,  Samuel J. Gillett ,  Tien T. Duong ,  Sunil Nagpal ,  Vidyasagar Vuligonda ,  Min Teng ,  Roshantha A. Chandraratna

IPC分类号： C07C6306

CPC分类号： C07D335/06 ,  C07C57/50 ,  C07C63/33 ,  C07C63/49 ,  C07C63/66 ,  C07C63/72 ,  C07C63/74 ,  C07C65/19 ,  C07C65/28 ,  C07C65/38 ,  C07C69/618 ,  C07C69/76 ,  C07C69/90 ,  C07C69/94 ,  C07C233/81 ,  C07C245/10 ,  C07C327/48 ,  C07C2602/10 ,  C07D213/55 ,  C07D277/30 ,  C07D307/54 ,  C07D333/24 ,  C07D409/04 ,  C07D417/04 ,  C07F7/081

摘要： Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

摘要翻译： 芳基取代的和芳基和（3-氧代-1-丙烯基）取代的苯并吡喃，苯并噻喃，1,2-二氢喹啉和5,6-二氢萘衍生物具有类视黄醇阴性激素和/或拮抗剂样生物活性。 本发明的RAR拮抗剂可以施用于包括人在内的哺乳动物，以预防或减少RAR激动剂在结合受体位点上的作用。 具体来说，RAR激动剂与类视黄醇药物一起施用或共同施用以预防或改善由类维生素A或维生素A或维生素A前体引起的毒性或副作用。 类视黄醇阴性激素可用于增强其他类维生素A和核受体激动剂的活性。 例如，称为AGN 193109的类视黄醇阴性激素有效地增加了体外反式激活测定中其他类维生素A和类固醇激素的有效性。 另外，反式激活测定可用于鉴定具有负激素活性的化合物。 这些测定是基于负激素下调修饰的具有组成型转录激活子结构域的嵌合维甲酸受体的活性的能力。

公开(公告)号：US5952345A

公开(公告)日：1999-09-14

申请号：US871093

申请日：1997-06-09

申请人： Elliot S. Klein ,  Alan T. Johnson ,  Andrew M. Standeven ,  Richard L. Beard ,  Samuel J. Gillett ,  Tien T. Duong ,  Sunil Nagpal ,  Vidyasagar Vuligonda ,  Min Teng ,  Roshantha A. Chandraratna

发明人： Elliot S. Klein ,  Alan T. Johnson ,  Andrew M. Standeven ,  Richard L. Beard ,  Samuel J. Gillett ,  Tien T. Duong ,  Sunil Nagpal ,  Vidyasagar Vuligonda ,  Min Teng ,  Roshantha A. Chandraratna

IPC分类号： A61K31/165 ,  A61K31/19 ,  A61K31/216 ,  A61K31/35 ,  A61K31/353 ,  A61K31/38 ,  A61K31/382 ,  A61K31/47 ,  A61K31/495 ,  A61K31/655 ,  C07C57/50 ,  C07C63/06 ,  C07C63/33 ,  C07C63/49 ,  C07C63/66 ,  C07C63/72 ,  C07C63/74 ,  C07C65/19 ,  C07C65/28 ,  C07C65/38 ,  C07C69/618 ,  C07C69/76 ,  C07C69/90 ,  C07C69/94 ,  C07C233/81 ,  C07C245/10 ,  C07C327/48 ,  C07D213/55 ,  C07D215/14 ,  C07D277/30 ,  C07D307/54 ,  C07D311/04 ,  C07D311/58 ,  C07D333/24 ,  C07D335/06 ,  C07D401/12 ,  C07D405/06 ,  C07D409/14 ,  C07F7/04 ,  C07F7/08 ,  C07D215/16

CPC分类号： C07C57/50 ,  C07C233/81 ,  C07C245/10 ,  C07C327/48 ,  C07C63/33 ,  C07C63/49 ,  C07C63/66 ,  C07C63/72 ,  C07C63/74 ,  C07C65/19 ,  C07C65/28 ,  C07C65/38 ,  C07C69/618 ,  C07C69/76 ,  C07C69/90 ,  C07C69/94 ,  C07D213/55 ,  C07D277/30 ,  C07D307/54 ,  C07D333/24 ,  C07D335/06 ,  C07D409/04 ,  C07D417/04 ,  C07F7/0818 ,  C07C2102/10

摘要： Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

公开(公告)号：US6090810A

公开(公告)日：2000-07-18

申请号：US222984

申请日：1998-12-30

申请人： Elliott S. Klein ,  Alan T. Johnson ,  Andrew M. Standeven ,  Richard L. Beard ,  Samuel J. Gillett ,  Tien T. Duong ,  Sunil Nagpal ,  Vidyasagar Vuligonda ,  Min Teng ,  Roshantha A. Chandraratna

发明人： Elliott S. Klein ,  Alan T. Johnson ,  Andrew M. Standeven ,  Richard L. Beard ,  Samuel J. Gillett ,  Tien T. Duong ,  Sunil Nagpal ,  Vidyasagar Vuligonda ,  Min Teng ,  Roshantha A. Chandraratna

IPC分类号： A61K31/165 ,  A61K31/19 ,  A61K31/216 ,  A61K31/35 ,  A61K31/353 ,  A61K31/38 ,  A61K31/382 ,  A61K31/47 ,  A61K31/495 ,  A61K31/655 ,  C07C57/50 ,  C07C63/06 ,  C07C63/33 ,  C07C63/49 ,  C07C63/66 ,  C07C63/72 ,  C07C63/74 ,  C07C65/19 ,  C07C65/28 ,  C07C65/38 ,  C07C69/618 ,  C07C69/76 ,  C07C69/90 ,  C07C69/94 ,  C07C233/81 ,  C07C245/10 ,  C07C327/48 ,  C07D213/55 ,  C07D215/14 ,  C07D277/30 ,  C07D307/54 ,  C07D311/04 ,  C07D311/58 ,  C07D333/24 ,  C07D335/06 ,  C07D401/12 ,  C07D405/06 ,  C07D409/14 ,  C07F7/04 ,  C07F7/08

CPC分类号： C07C57/50 ,  C07C233/81 ,  C07C245/10 ,  C07C327/48 ,  C07C63/33 ,  C07C63/49 ,  C07C63/66 ,  C07C63/72 ,  C07C63/74 ,  C07C65/19 ,  C07C65/28 ,  C07C65/38 ,  C07C69/618 ,  C07C69/76 ,  C07C69/90 ,  C07C69/94 ,  C07D213/55 ,  C07D277/30 ,  C07D307/54 ,  C07D333/24 ,  C07D335/06 ,  C07D409/04 ,  C07D417/04 ,  C07F7/0818 ,  C07C2102/10

摘要： Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

公开(公告)号：US6008204A

公开(公告)日：1999-12-28

申请号：US222983

申请日：1998-12-30

申请人： Elliott S. Klein ,  Alan T. Johnson ,  Andrew M. Standeven ,  Richard L. Beard ,  Samuel J. Gillett ,  Tien T. Duong ,  Sunil Nagpal ,  Vidyasagar Vuligonda ,  Min Teng ,  Roshantha A. Chandraratna

发明人： Elliott S. Klein ,  Alan T. Johnson ,  Andrew M. Standeven ,  Richard L. Beard ,  Samuel J. Gillett ,  Tien T. Duong ,  Sunil Nagpal ,  Vidyasagar Vuligonda ,  Min Teng ,  Roshantha A. Chandraratna

IPC分类号： A61K31/165 ,  A61K31/19 ,  A61K31/216 ,  A61K31/35 ,  A61K31/353 ,  A61K31/382 ,  A61K31/47 ,  A61K31/655 ,  C07C57/50 ,  C07C63/06 ,  C07C63/33 ,  C07C63/49 ,  C07C63/66 ,  C07C63/72 ,  C07C63/74 ,  C07C65/19 ,  C07C65/28 ,  C07C65/38 ,  C07C69/618 ,  C07C69/76 ,  C07C69/90 ,  C07C69/94 ,  C07C233/81 ,  C07C245/10 ,  C07C327/48 ,  C07D213/55 ,  C07D215/14 ,  C07D277/30 ,  C07D307/54 ,  C07D311/04 ,  C07D311/58 ,  C07D333/24 ,  C07D335/06 ,  C07D401/12 ,  C07D405/06 ,  C07D409/14 ,  C07F7/04 ,  C07F7/08

CPC分类号： C07D335/06 ,  C07C233/81 ,  C07C245/10 ,  C07C327/48 ,  C07C57/50 ,  C07C63/33 ,  C07C63/49 ,  C07C63/66 ,  C07C63/72 ,  C07C63/74 ,  C07C65/19 ,  C07C65/28 ,  C07C65/38 ,  C07C69/618 ,  C07C69/76 ,  C07C69/90 ,  C07C69/94 ,  C07D213/55 ,  C07D277/30 ,  C07D307/54 ,  C07D333/24 ,  C07D409/04 ,  C07D417/04 ,  C07F7/0818 ,  C07C2102/10

摘要： Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

公开(公告)号：US06521624B1

公开(公告)日：2003-02-18

申请号：US09535042

申请日：2000-03-23

申请人： Elliott S. Klein ,  Alan T. Johnson ,  Andrew M. Standeven ,  Richard L. Beard ,  Samuel J. Gillett ,  Tien T. Duong ,  Sunil Nagpal ,  Vidyasagar Vuligonda ,  Min Teng ,  Roshantha A. Chandraratna

发明人： Elliott S. Klein ,  Alan T. Johnson ,  Andrew M. Standeven ,  Richard L. Beard ,  Samuel J. Gillett ,  Tien T. Duong ,  Sunil Nagpal ,  Vidyasagar Vuligonda ,  Min Teng ,  Roshantha A. Chandraratna

IPC分类号： A61K31495

CPC分类号： C07C57/50 ,  C07C63/33 ,  C07C63/49 ,  C07C63/66 ,  C07C63/72 ,  C07C63/74 ,  C07C65/19 ,  C07C65/28 ,  C07C65/38 ,  C07C69/618 ,  C07C69/76 ,  C07C69/90 ,  C07C69/94 ,  C07C233/81 ,  C07C245/10 ,  C07C327/48 ,  C07C2602/10 ,  C07D213/55 ,  C07D277/30 ,  C07D307/54 ,  C07D333/24 ,  C07D335/06 ,  C07D409/04 ,  C07D417/04 ,  C07F7/081

摘要： Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

公开(公告)号：US06469028B1

公开(公告)日：2002-10-22

申请号：US09821673

申请日：2001-03-28

申请人： Elliott S. Klein ,  Alan T. Johnson ,  Andrew M. Standeven ,  Richard L. Beard ,  Samuel J. Gillett ,  Tien T. Duong ,  Sunil Nagpal ,  Vidyasagar Vuligonda ,  Min Teng ,  Roshantha A. Chandraratna

发明人： Elliott S. Klein ,  Alan T. Johnson ,  Andrew M. Standeven ,  Richard L. Beard ,  Samuel J. Gillett ,  Tien T. Duong ,  Sunil Nagpal ,  Vidyasagar Vuligonda ,  Min Teng ,  Roshantha A. Chandraratna

IPC分类号： C07D21514

CPC分类号： C07D335/06 ,  C07C57/50 ,  C07C63/33 ,  C07C63/49 ,  C07C63/66 ,  C07C63/72 ,  C07C63/74 ,  C07C65/19 ,  C07C65/28 ,  C07C65/38 ,  C07C69/618 ,  C07C69/76 ,  C07C69/90 ,  C07C69/94 ,  C07C233/81 ,  C07C245/10 ,  C07C327/48 ,  C07C2602/10 ,  C07D213/55 ,  C07D277/30 ,  C07D307/54 ,  C07D333/24 ,  C07D409/04 ,  C07D417/04 ,  C07F7/081

摘要： Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

摘要翻译： 芳基取代的和芳基和（3-氧代-1-丙烯基）取代的苯并吡喃，苯并噻喃，1,2-二氢喹啉和5,6-二氢萘衍生物具有类视黄醇阴性激素和/或拮抗剂样生物活性。 本发明的RAR拮抗剂可以施用于包括人在内的哺乳动物，以预防或减少RAR激动剂在结合受体位点上的作用。 具体来说，RAR激动剂与类视黄醇药物一起施用或共同施用以预防或改善由类维生素A或维生素A或维生素A前体引起的毒性或副作用。 类视黄醇阴性激素可用于增强其他类维生素A和核受体激动剂的活性。 例如，称为AGN 193109的类视黄醇阴性激素有效地增加了体外反式激活测定中其他类维生素A和类固醇激素的有效性。 另外，反式激活测定可用于鉴定具有负激素活性的化合物。 这些测定是基于负激素下调修饰的具有组成型转录激活子结构域的嵌合维甲酸受体的活性的能力。